Attenuon, LLC - Product Pipeline Review - H2 2011

Attenuon, LLC – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Attenuon, LLC - Product Pipeline Review - H2 2011” provides data on the Attenuon, LLC’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Attenuon, LLC’s corporate website, SEC filings, investor presentations and featured press releases, both from Attenuon, LLC and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Attenuon, LLC - Brief Attenuon, LLC overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Attenuon, LLC human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Attenuon, LLC with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Attenuon, LLC’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Attenuon, LLC’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Attenuon, LLC in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Attenuon, LLC’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Attenuon, LLC.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Attenuon, LLC and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Attenuon, LLC; Attenuon, LLC - Key Therapeutics; Attenuon, LLC - Pipeline Overview and Promising Molecules; Attenuon, LLC - News; Attenuon, LLC - Latest Updates; Attenuon, LLC - Pipeline; Attenuon, LLC - Discontinued/Dormant Projects SHOW LESS READ MORE >

List of Tables
List of Figures
Attenuon, LLC Snapshot
Attenuon, LLC Overview
Key Information
Key Facts
Attenuon, LLC – Research and Development Overview
Key Therapeutic Areas
Attenuon, LLC – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Attenuon, LLC – Pipeline Products Glance
Attenuon, LLC Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Attenuon, LLC–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Attenuon, LLC – Drug Profiles
ATN-161 + Carboplatin
Product Description
Mechanism of Action
R&D Progress
ATN-224
Product Description
Mechanism of Action
R&D Progress
huATN-658
Product Description
Mechanism of Action
R&D Progress
Attenuon, LLC – Pipeline Analysis
Attenuon, LLC – Pipeline Products by Therapeutic Class
Attenuon, LLC - Pipeline Products By Target
Attenuon, LLC – Pipeline Products by Route of Administration
Attenuon, LLC – Pipeline Products by Molecule Type
Attenuon, LLC - Dormant Projects
Attenuon, LLC - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ATN-161
ATN-224 + Velcade
Attenuon, LLC – Locations And Subsidiaries
Head Office
Recent Developments
Jan 30, 2003: Attenuon Launches Phase I Trial Of ATN-161
Mar 29, 2004: Data From Preclinical Studies Examining Effect Of ATN-161 On Organ And Skeletal Metastases Of Breast Cancer Presented At American Association For Cancer Research Annual Meeting
Oct 28, 2004: Attenuon Receives NIH Grant To Study ATN-161 Analogs As Cancer Imaging Agents
May 24, 2004: Attenuon Announces Launch Of ATN-224 Phase I Trial In Patients With Solid Tumors
Financial Deals Landscape
Attenuon, LLC, Deals Summary
Attenuon, LLC, Pharmaceuticals & Healthcare, Deal Details
Partnerships
XOMA And Attenuon Enter Into Co-Development Agreement To Humanize Novel Anti-Cancer Antibody
Attenuon Enters Into Co-Development Agreement With Kirin Brewery
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Attenuon, LLC – Pipeline by Therapy Area and Indication, H2 2011
Attenuon, LLC – Pipeline by Stage of Development, H2 2011
Attenuon, LLC – Monotherapy Products in Pipeline, H2 2011
Attenuon, LLC – Combination Treatment Modalities in Pipeline, H2 2011
Attenuon, LLC - Phase II, H2 2011
Attenuon, LLC - Pipeline By Therapeutic Class, H2 2011
Attenuon, LLC - Pipeline By Target, H2 2011
Attenuon, LLC – Pipeline By Route of Administration, H2 2011
Attenuon, LLC – Pipeline By Molecule Type, H2 2011
Attenuon, LLC - Dormant Developmental Projects, 2010
Attenuon, LLC - Discontinued Pipeline Products, 2010
Attenuon, LLC, Deals Summary
XOMA And Attenuon Enter Into Co-Development Agreement To Humanize Novel Anti-Cancer Antibody
Attenuon Enters Into Co-Development Agreement With Kirin Brewery

List of Figures
Attenuon, LLC – Pipeline by Therapy Area and Indication, H2 2011
Attenuon, LLC – Pipeline by Stage of Development, H2 2011
Attenuon, LLC – Monotherapy Products in Pipeline, H2 2011
Attenuon, LLC – Combination Treatment Modalities in Pipeline, H2 2011
Attenuon, LLC – Pipeline By Therapeutic Class, H2 2011
Attenuon, LLC - Pipeline By Target, H2 2011
Attenuon, LLC – Pipeline By Molecule Type, H2 2011